Radiotherapy and tamoxifen after mastectomy in postmenopausal women - 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II : I
(2007) In European Journal of Cancer 43(14). p.2100-2108- Abstract
- Aims: To evaluate long-term effects of radiotherapy and tamoxifen after mastectomy on recurrence and survival in stage II breast cancer. Methods: A randomised phase III study with three treatment alternatives. (1) Radiotherapy 50 Gy/2S fractions to chest wall and regional lymph nodes (RT). (2) Radiotherapy and tamoxifen 30 mg/day for one year (RT + tam) and 3. Tamoxifen (tam). Results: 724 postmenopausal women were included between 1978 and 1985 and the trial was close to population based. Follow-up for survival was 23 years. Locoregional recurrences were reduced from 18.5% in the tam arm to 5.3% in the RT + tam arm. Overall mortality at 20 years was 71% in the RT arm, 68% in the RT + tam arm and 62% in the tam arm. The difference between... (More)
- Aims: To evaluate long-term effects of radiotherapy and tamoxifen after mastectomy on recurrence and survival in stage II breast cancer. Methods: A randomised phase III study with three treatment alternatives. (1) Radiotherapy 50 Gy/2S fractions to chest wall and regional lymph nodes (RT). (2) Radiotherapy and tamoxifen 30 mg/day for one year (RT + tam) and 3. Tamoxifen (tam). Results: 724 postmenopausal women were included between 1978 and 1985 and the trial was close to population based. Follow-up for survival was 23 years. Locoregional recurrences were reduced from 18.5% in the tam arm to 5.3% in the RT + tam arm. Overall mortality at 20 years was 71% in the RT arm, 68% in the RT + tam arm and 62% in the tam arm. The difference between RT + tam and tam was not significant except in the receptor positive subgroup in favour of non-irradiated patients (p = 0.047). The cumulative incidence of systemic disease at 20 years was lower in the RT + Tam arm than in the RT arm, 40% versus 50% (p = 0.047). Conclusion: Postmastectomy radiotherapy significantly reduced loco-regional recurrences, but overall survival was not improved. At 20 years, a lower mortality was recorded for non-irradiated patients treated with tam. (C) 2007 Published by Elsevier Ltd. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/655358
- author
- Killander, Fredrika LU ; Anderson, Harald LU ; Ryden, Stefan ; Möller, Torgil LU ; Aspegrend, Knut ; Ceberg, Jeanette ; Danewid, Christina and Malmström, Per LU
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- local recurrence, radiotherapy, breast cancer, mastectomy, mortality, long-term, tamoxifen
- in
- European Journal of Cancer
- volume
- 43
- issue
- 14
- pages
- 2100 - 2108
- publisher
- Elsevier
- external identifiers
-
- wos:000250186100019
- scopus:34548479956
- pmid:17644330
- ISSN
- 1879-0852
- DOI
- 10.1016/j.ejca.2007.05.026
- language
- English
- LU publication?
- yes
- id
- 68ef6c1b-942b-434e-aec1-c1f84a6fe376 (old id 655358)
- date added to LUP
- 2016-04-01 12:25:27
- date last changed
- 2022-04-21 07:16:04
@article{68ef6c1b-942b-434e-aec1-c1f84a6fe376, abstract = {{Aims: To evaluate long-term effects of radiotherapy and tamoxifen after mastectomy on recurrence and survival in stage II breast cancer. Methods: A randomised phase III study with three treatment alternatives. (1) Radiotherapy 50 Gy/2S fractions to chest wall and regional lymph nodes (RT). (2) Radiotherapy and tamoxifen 30 mg/day for one year (RT + tam) and 3. Tamoxifen (tam). Results: 724 postmenopausal women were included between 1978 and 1985 and the trial was close to population based. Follow-up for survival was 23 years. Locoregional recurrences were reduced from 18.5% in the tam arm to 5.3% in the RT + tam arm. Overall mortality at 20 years was 71% in the RT arm, 68% in the RT + tam arm and 62% in the tam arm. The difference between RT + tam and tam was not significant except in the receptor positive subgroup in favour of non-irradiated patients (p = 0.047). The cumulative incidence of systemic disease at 20 years was lower in the RT + Tam arm than in the RT arm, 40% versus 50% (p = 0.047). Conclusion: Postmastectomy radiotherapy significantly reduced loco-regional recurrences, but overall survival was not improved. At 20 years, a lower mortality was recorded for non-irradiated patients treated with tam. (C) 2007 Published by Elsevier Ltd.}}, author = {{Killander, Fredrika and Anderson, Harald and Ryden, Stefan and Möller, Torgil and Aspegrend, Knut and Ceberg, Jeanette and Danewid, Christina and Malmström, Per}}, issn = {{1879-0852}}, keywords = {{local recurrence; radiotherapy; breast cancer; mastectomy; mortality; long-term; tamoxifen}}, language = {{eng}}, number = {{14}}, pages = {{2100--2108}}, publisher = {{Elsevier}}, series = {{European Journal of Cancer}}, title = {{Radiotherapy and tamoxifen after mastectomy in postmenopausal women - 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II : I}}, url = {{http://dx.doi.org/10.1016/j.ejca.2007.05.026}}, doi = {{10.1016/j.ejca.2007.05.026}}, volume = {{43}}, year = {{2007}}, }